Drug Profile


Alternative Names: BB 608; BBI 608 DP1; BBI 608 DP2A; BBI-608; DP1; DP2A

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Boston Biomedical
  • Developer Boston Biomedical; Sumitomo Dainippon Pharma
  • Class Antineoplastics; Furans; Naphthoquinones; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Cell death stimulants; STAT3 transcription factor inhibitors; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase I/II Glioblastoma; Hepatocellular carcinoma; Mesothelioma; Solid tumours
  • Phase I Gastrointestinal cancer; Haematological malignancies

Most Recent Events

  • 04 Mar 2017 Pharmacodynamics data from a preclinical study in Colorectal cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017).
  • 21 Jan 2017 Efficacy and adverse event data from two phase Ib/II trials in Colorectal cancer presented at the 2017 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI-2017)
  • 21 Jan 2017 Efficacy data from a phase Ib/II and a phase II trial in Colorectal cancer released by Boston Biomedical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top